For the quarter ending 2025-09-30, CDIOW had -$1,611,282 decrease in cash & cash equivalents over the period. -$1,556,252 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,714,536 | -3,318,263 |
| Depreciation | 40,402 | 75,441 |
| Amortization | 49,186 | 139,022 |
| Stock-based compensation expense | 24,762 | 61,390 |
| Accounts receivable | -1,706 | -5,685 |
| Prepaid expenses and other current assets | -162,888 | -220,762 |
| Accounts payable and accrued expenses | 102,010 | -38,937 |
| Lease liability | -59,836 | -116,666 |
| Net cash used in operating activities | -1,393,418 | -2,971,566 |
| Purchases of property and equipment | 162,834 | 24,483 |
| Patent costs incurred | 94,985 | 58,649 |
| Net cash used in investing activities | -257,819 | -83,132 |
| Proceeds from sale of common stock and warrants, net of issuance costs | 116,646 | 3,423,784 |
| Payments of finance agreement | 76,691 | 230,073 |
| Net cash provided by financing activities | 39,955 | 3,193,711 |
| Net (decrease) increase in cash | -1,611,282 | 139,013 |
| Cash and cash equivalents at beginning of period | 7,827,487 | - |
| Cash and cash equivalents at end of period | 6,355,218 | - |
Cardio Diagnostics Holdings, Inc. (CDIOW)
Cardio Diagnostics Holdings, Inc. (CDIOW)